Advertisement

Topics

Kyowa Hakko Kirin Co. Ltd. Company Profile

13:47 EDT 19th April 2018 | BioPortfolio


News Articles [144 Associated News Articles listed on BioPortfolio]

Kyowa Kirin und Ultragenyx geben bekannt, dass Crysvita® (Burosumab) eine bedingte Zulassung ...

Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) und Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) gaben Read more...

Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority Review Designation of Mogamulizumab Biologics License Application

TOKYO--(BUSINESS WIRE)-- November 28, 2017 Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151) (President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announces that the U.S. Food and Drug Administration...

Ultragenyx und Kyowa Kirin geben bekannt, dass Burosumab eine positive Stellungnahme des CHMP zur Behandlung der X-chromosomalen Hypophosphatämie bei Kindern erhalten hat

Tokio, London, und Novato, Kalifornien (ots/PRNewswire) - Bei Zulassung wäre Burosumab die erste gezielte krankheitsmodifizierende Behandlung für XLH Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin)....

Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

TOKYO, December 11, 2017 /PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that the results of the Global Phase 3 study...

FDA accepts Kyowa Hakko Kirin’s BLA for lymphoma candidate

Shares of Japanese drugmaker Kyowa Hakko Kirin moved up more than 2% to 2,086 yen today, after the company…

FDA Approves Crysvita, The First Therapy for X-Linked Hypophosphatemia, A Rare Inherited Form of Rickets

NOVATO, Calif. and TOKYO and LONDON, April 17, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel produ...

Kyowa Hakko Kirin to market tenapanor for cardiorenal diseases in Japan

Ardelyx has entered into a license agreement that provides Japan’s Kyowa Hakko Kirin with exclusive…

Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children

TOKYO, LONDON, and NOVATO, California, December 15, 2017 /PRNewswire/ -- If approved, burosumabwould be the first targeted disease-modifying treatment for XLH Kyowa Hakko Kirin Co., Ltd. (Kyowa Ha...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [17 Associated Companies listed on BioPortfolio]

Kyowa Hakko Kirin Co. Ltd.

Kyowa Hakko Kirin Co., Ltd.

Kyowa Pharmaceutical, Inc

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered...

Kyowa Hakko

Kyowa Hakko USA

More Information about "Kyowa Hakko Kirin Co. Ltd." on BioPortfolio

We have published hundreds of Kyowa Hakko Kirin Co. Ltd. news stories on BioPortfolio along with dozens of Kyowa Hakko Kirin Co. Ltd. Clinical Trials and PubMed Articles about Kyowa Hakko Kirin Co. Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kyowa Hakko Kirin Co. Ltd. Companies in our database. You can also find out about relevant Kyowa Hakko Kirin Co. Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record